A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

Abstract Background 68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist exhibiting higher tumour-to-background ratios and sensitivity compared to 68Ga-DOTATOC. This randomised, 2 × 3 factorial, phase II study aimed to confirm the optimal peptide mass and radioactivity ranges for...

Full description

Bibliographic Details
Main Authors: Colin G. Miller, Henning Grønbæk, Irene Virgolini, Andreas Kjaer, Pierre Terve, Shadfar Bahri, Peter Iversen, Hanna Svirydenka, Thomas Rohban, Sandy McEwan
Format: Article
Language:English
Published: SpringerOpen 2021-09-01
Series:EJNMMI Research
Subjects:
68Ga-satoreotide trizoxetan
Neuroendocrine tumours
Somatostatin receptor antagonist
Diagnostic imaging
Binary visual reading
Online Access:https://doi.org/10.1186/s13550-021-00819-1

Internet

https://doi.org/10.1186/s13550-021-00819-1

Similar Items